Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery It operates in two segments, Codman Specialty Surgical and Tissue Technologies.
infoIntegra LifeSciences is a mid cap stock with a total market cap of 3.46B.
infoThey trade on the NASDAQ and had their IPO 28 years ago.
infoIntegra LifeSciences currently employs 3722 people.
infoAs of Wednesday, Aug 23 2023, Integra LifeSciences’s share price is $42.5.
News Relating to Integra LifeSciences
Seeking Alpha
Integra LifeSciences: Uncertainties To Intrinsic Value Remain, Reiterate Hold
Friday Aug 18 2023 at 01:00
Integra LifeSciences Holdings Corporation faces uncertainties and challenges due to the ongoing issues at its Boston manufacturing facility. The company’s financials have been impacted by this, despite reasonable organic growth in the rest of its core portfolio. The stock’s negative sentiment, compressed valuations, and lack of secondary catalysts suggest limited upside potential.
Zacks Investment Research
Integra’s (IART) Q2 Earnings Top Estimates, 2023 View Cut
Friday Jul 28 2023 at 12:32
In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.
Zacks Investment Research
Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates
Wednesday Jul 26 2023 at 21:26
Integra LifeSciences (IART) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.82 per share a year ago.
Zacks Investment Research
Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Wednesday Jul 26 2023 at 21:26
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research
Integra’s (IART) Codman EVD Catheter Study Data Favorable
Tuesday Jul 11 2023 at 12:32
Integra’s (IART) Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus.
GlobeNewsWire
Integra LifeSciences to Host Second Quarter 2023 Financial Results Conference Call on July 27, 2023
Monday Jul 03 2023 at 16:45
PRINCETON, N.J., July 03, 2023 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2023 financial results on Thursday, July 27, 2023, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.
Zacks Investment Research
Integra (IART) Completes Enrollment in the DuraSorb IDE Study
Thursday Jun 29 2023 at 09:53
Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.
Zacks Investment Research
New Strong Sell Stocks for June 29th
Thursday Jun 29 2023 at 09:08
NGVT, IART and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2023.
Zacks Investment Research
Here’s Why You Should Retain Integra (IART) Stock Now
Tuesday May 30 2023 at 09:09
Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.
The Motley Fool
Why Integra LifeSciences Stock Is Crashing Today
Tuesday May 23 2023 at 15:52
Integra announced a global recall of products made at its Boston facility. The company is also temporarily halting production at the facility.
Proactive Investors
Integra LifeSciences tumbles after product recall
Tuesday May 23 2023 at 11:21
Integra Lifesciences Holdings Corp (NASDAQ:IART) shares fell hard after it disclosed that after consultations with the US Food and Drug Administration (FDA) it has initiated a “voluntary global recall” of all products manufactured in its Boston facility distributed between March 1, 2018, and May 22, 2023. The Princeton, New Jersey-based medical device manufacturing company said that it expects it will incur an impairment charge related to the write-off of inventories, net of approximately $22 million.
Zacks Investment Research
Integra (IART) Builds Advanced R&D Facility in New Jersey
Monday May 15 2023 at 09:09
Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.
Zacks Investment Research
Integra’s (IART) Q1 Earnings Match Estimates, Margins Contract
Thursday Apr 27 2023 at 12:10
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
Zacks Investment Research
Integra LifeSciences (IART) Q1 Earnings Meet Estimates
Wednesday Apr 26 2023 at 08:24
Integra LifeSciences (IART) came out with quarterly earnings of $0.74 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.74 per share a year ago.
GlobeNewsWire
Integra LifeSciences to Host First Quarter 2023 Financial Results Conference Call on April 26, 2023
Monday Apr 03 2023 at 08:00
PRINCETON, N.J., April 03, 2023 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2023 financial results on Wednesday, April 26, 2023, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.
Zacks Investment Research
Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y
Thursday Feb 23 2023 at 09:47
Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.
Seeking Alpha
Integra LifeSciences Holdings Corporation (IART) Q4 2022 Earnings Call Transcript
Wednesday Feb 22 2023 at 14:56
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q4 2022 Earnings Conference Call February 22, 2023 8:30 AM ET Company Participants Chris Ward – Senior Director, Investor Relations Jan De Witte – President & Chief Executive Officer Jeffrey Mosebrook – SVP, Chief Accounting Officer Mathieu Aussermeier – VP, Corporate FP&A, Investor Relations & Treasurer Conference Call Participants Vik Chopra – Wells Fargo Steve Lichtman – Oppenheimer & Co. Matthew Taylor – Jefferies Ryan Zimmerman – BTIG Richard Newitter – Truist Securities Jayson Bedford – Raymond James David Turkaly – JMP Securities Matthew O’Brien – Piper Sandler Operator Thank you for standing by and welcome to Integra LifeSciences Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.
Zacks Investment Research
Integra LifeSciences (IART) Tops Q4 Earnings and Revenue Estimates
Wednesday Feb 22 2023 at 09:02
Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth
Wednesday Feb 15 2023 at 11:17
Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewsWire
Integra LifeSciences to Host Fourth Quarter 2022 Financial Results Conference Call on February 22, 2023
Thursday Feb 09 2023 at 07:30
PRINCETON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter 2022 financial results on Wednesday, February 22, 2023, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.
Zacks Investment Research
3 MedTech Stocks Likely to Beat Estimates This Earnings Season
Wednesday Feb 08 2023 at 09:02
MedTech companies’ results are likely to reflect base business recovery on a year-over-year basis. Let’s see how EXAS, MDT and IART are poised ahead of their earnings releases.
Zacks Investment Research
Why Integra (IART) Could Beat Earnings Estimates Again
Thursday Jan 26 2023 at 13:33
Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GlobeNewsWire
Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference
Wednesday Dec 21 2022 at 17:00
PRINCETON, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president and chief executive officer will present at the 41st Annual J.P. Morgan Healthcare conference on January 11, 2023 at 7:30pm ET.
Zacks Investment Research
Integra’s (IART) SIA Buyout Widens Breast Reconstruction Scope
Tuesday Dec 13 2022 at 12:02
With the acquisition, SIA’s DuraSorb’s resorbable synthetic technology is expected to strengthen Integra’s (IART) plastic and reconstructive surgery portfolio.
Seeking Alpha
Integra LifeSciences: Alpha Opportunity Playing Out, Reaffirm Buy
Friday Dec 02 2022 at 12:18
The CereLink overhang is largely removed, with Integra LifeSciences actively providing an intermediate solution to customers. Divisional strengths were the highlight in Q3 versus absolute numbers throughout the P&L.
Zacks Investment Research
Integra’s (IART) Q3 Earnings Top, Gross Margin Declines
Thursday Oct 27 2022 at 13:32
Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.
Seeking Alpha
Integra LifeSciences Holdings Corporation (IART) Q3 2022 – Earnings Call Transcript
Wednesday Oct 26 2022 at 15:19
Integra LifeSciences Holdings Corporation. (NASDAQ:IART ) Q3 2022 Earnings Conference Call October 26, 2022 8:30 AM ET Company Participants Chris Ward – Senior Director, Investor Relations Jan De Witte – President & Chief Executive Officer Carrie Anderson – Chief Financial Officer Conference Call Participants Ryan Zimmerman – BTIG David Turkaly – JPM Vik Chopra – Wells Fargo Matthew Taylor – Jefferies Steve Lichtman – Oppenheimer Drew Ranieri – Morgan Stanley Richard Newitter – Truist Operator Hello and welcome to the Integra LifeScience Third Quarter 2022 Financial Results.
Zacks Investment Research
Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates
Wednesday Oct 26 2022 at 08:17
Integra (IART) delivered earnings and revenue surprises of 19.44% and 1.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Integra LifeSciences to Host Third Quarter 2022 Financial Results Conference Call on October 26, 2022
Friday Oct 07 2022 at 16:30
PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2022 financial results on Wednesday, October 26, 2022, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.
Zacks Investment Research
Here’s Why Investors Should Retain Integra (IART) Stock for Now
Friday Sep 16 2022 at 13:33
Investors are optimistic about Integra’s (IART) better-than-expected results and the continued demand for its products.
Integra LifeSciences Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Integra LifeSciences’s Altman Z-score is 2.26 which is in the gray zone. This indicates a level of ambiguity where further analyses are needed to evaluate the company’s financial stability accurately.
Derived from SEC.GOV filing dataopen_in_new
Integra LifeSciences Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $52.33K of common stock in Integra LifeSciences on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Integra LifeSciences’s Income Quality of 1.59 is greater than its Industry Group of 0.68 (133.8% greater)
Integra LifeSciences’s Income Quality of 1.59 is greater than its Major Industry Group of 0.71 (123.9% greater)
Integra LifeSciences’s Income Quality of 1.59 is greater than its Sector of 0.75 (112.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Integra LifeSciences’s Current Ratio of 2.78 is lower than its Industry Group of 3.36 (-17.3% lower)
Integra LifeSciences’s Current Ratio of 2.78 is lower than its Major Industry Group of 3.13 (-11.2% lower)
Integra LifeSciences’s Current Ratio of 2.78 is in line with its Sector of 2.6 (6.9% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (26.36 & -1.02)
Cannot compare a negative PE Ratio (26.36 & -0.58)
Cannot compare a negative PE Ratio (26.36 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Integra LifeSciences’s PB Ratio of 2.06 is in line with its Industry Group of 1.9 (8.4% greater)
Integra LifeSciences’s PB Ratio of 2.06 is in line with its Major Industry Group of 1.93 (6.7% greater)
Integra LifeSciences’s PB Ratio of 2.06 is greater than its Sector of 1.62 (27.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Integra LifeSciences’s ROE of 0.08 is greater than its Industry Group of -0.26 (130.8% greater)
Integra LifeSciences’s ROE of 0.08 is greater than its Major Industry Group of -0.09 (188.9% greater)
Integra LifeSciences’s ROE of 0.08 is greater than its Sector of -0.03 (366.7% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Integra LifeSciences’s ROCE of 0.05 is greater than its Industry Group of -0.27 (118.5% greater)
Integra LifeSciences’s ROCE of 0.05 is greater than its Major Industry Group of -0.14 (135.7% greater)
Integra LifeSciences’s ROCE of 0.05 is greater than its Sector of -0.04 (225.0% greater)
Derived from SEC.GOV filing dataopen_in_new